Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Virchows Archiv
Erschienen in: Virchows Archiv 6/2022

14.05.2022 | Review

The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS

verfasst von: Edi Brogi

Erschienen in: Virchows Archiv | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Lobular carcinoma in situ (LCIS) is a non-invasive proliferation of atypical dyscohesive epithelial cells characterized by loss or functional alteration of E-cadherin-mediated cell adhesion. The morphologic spectrum of LCIS encompasses classic (C-LCIS), florid (F-LCIS) and pleomorphic LCIS (P-LCIS), as recently defined by the World Health Organization (WHO) Expert Consensus Group. Atypical lobular hyperplasia (ALH) is also part of this spectrum.
This article highlights the morphologic and immunohistochemical features of the three forms of LCIS and summarizes their management implications and prognosis, with emphasis on F-LCIS and P-LCIS.
Literatur
1.
WHO (2019) Classification of Tumours Editorial Board. Breast Tumours. 5th ed. IARC, Lyon, France
2.
Haagensen CD, Lane N, Lattes R, Bodian C (1978) Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 42(2):737–769CrossRef
3.
Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW (1991) Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 22(12):1232–1239CrossRef
4.
Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55(11):2698–2708CrossRef
5.
Foote FW, Stewart FW (1941) Lobular carcinoma in situ: A rare form of mammary cancer. Am J Pathol 17(4):491–463
6.
Lakhani SR, Collins N, Sloane JP, Stratton MR (1995) Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin Mol Pathol 48(2):M74–M78CrossRef
7.
Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM (1998) Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 58(20):4721–4727
8.
De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S et al (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183(4):404–411CrossRef
9.
Vos CB, Cleton-Jansen AM, Berx G, de Leeuw WJ, ter Haar NT, van Roy F et al (1997) E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 76(9):1131–1133CrossRef
10.
Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A et al (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163(2):506–519CrossRef
11.
Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M, Herman JG et al (2003) Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 106(2):208–215CrossRef
12.
Wang Y, Jindal S, Martel M, Wu Y, Schedin P, Troxell M (2016) Myoepithelial cells in lobular carcinoma in situ: distribution and immunophenotype. Hum Pathol 55:126–134CrossRef
13.
Sgroi D, Koerner FC (1995) Involvement of collagenous spherulosis by lobular carcinoma in situ. Potential confusion with cribriform ductal carcinoma in situ. Am J Surg Pathol 19(12):1366–1370
14.
King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A et al (2015) Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol 33(33):3945–3952CrossRef
15.
Wong SM, King T, Boileau JF, Barry WT, Golshan M (2017) Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Ann Surg Oncol 24(9):2509–2517CrossRef
16.
van Maaren MC, Avila AO, van Manen JG, Menke-Pluijmers MB, Veltman J, Bart J et al (2021) Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis. Breast 59:376–382CrossRef
17.
Li CI, Daling JR, Malone KE (2005) Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 14(4):1008–1011CrossRef
18.
Li CI, Anderson BO, Daling JR, Moe RE (2002) Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat 75(3):259–268CrossRef
19.
Cheng P, Huang Q, Shou J, Hu G, Han M, Huang J (2017) Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population based study. Oncotarget 8(61):103047–103054CrossRef
20.
Taylor LJ, Steiman J, Schumacher JR, Wilke LG, Greenberg CC, Neuman HB (2018) Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database. Ann Surg Oncol 25(8):2229–2234CrossRef
21.
Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW, Jr (1978) Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 2(3):225–251
22.
Salvadori B, Bartoli C, Zurrida S, Delledonne V, Squicciarini P, Rovini D et al (1991) Risk of invasive cancer in women with lobular carcinoma in situ of the breast. Eur J Cancer 27(1):35–37CrossRef
23.
Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA (1993) Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 17(1):14–21
24.
Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF (2003) Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 361(9352):125–129CrossRef
25.
Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM (2016) Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses’ Health Studies. Cancer 122(4):515–520CrossRef
26.
Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ (2007) Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses’ Health Study. Cancer 109(2):180–187CrossRef
27.
Degnim AC, Visscher DW, Radisky DC, Frost MH, Vierkant RA, Frank RD et al (2016) Breast cancer risk by the extent and type of atypical hyperplasia. Cancer 122(19):3087–3088CrossRef
28.
29.
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67–75CrossRef
30.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE et al (2020) Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 395(10218):117–122CrossRef
31.
Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391CrossRef
32.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388CrossRef
33.
Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, et al. (2019) Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 174(2):279–296
34.
Pinder SE, Shaaban A, Deb R, Desai A, Gandhi A, Lee AHS et al (2018) NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions). Clin Radiol 73(8):682–692CrossRef
35.
Murray MP, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E (2013) Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer 119(5):1073–1079CrossRef
36.
Niell B, Specht M, Gerade B, Rafferty E (2012) Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol 199(4):929–935CrossRef
37.
Zhao C, Desouki MM, Florea A, Mohammed K, Li X, Dabbs D (2012) Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification. Am J Clin Pathol 138(1):72–78CrossRef
38.
D’Alfonso TM, Wang K, Chiu YL, Shin SJ (2013) Pathologic upgrade rates on subsequent excision when lobular carcinoma in situ is the primary diagnosis in the needle core biopsy with special attention to the radiographic target. Arch Pathol Lab Med 137(7):927–935CrossRef
39.
Susnik B, Day D, Abeln E, Bowman T, Krueger J, Swenson KK et al (2016) Surgical Outcomes of Lobular Neoplasia Diagnosed in Core Biopsy: Prospective Study of 316 Cases. Clin Breast Cancer 16(6):507–513CrossRef
40.
Sen LQ, Berg WA, Hooley RJ, Carter GJ, Desouki MM, Sumkin JH (2016) Core Breast Biopsies Showing Lobular Carcinoma In Situ Should Be Excised and Surveillance Is Reasonable for Atypical Lobular Hyperplasia. AJR Am J Roentgenol 207(5):1132–1145CrossRef
41.
Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, Deperi ER, Glazebrook KN (2012) Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol 19(10):3131–3138CrossRef
42.
43.
Falomo E, Adejumo C, Carson KA, Harvey S, Mullen L, Myers K (2019) Variability in the Management Recommendations Given for High-risk Breast Lesions Detected on Image-guided Core Needle Biopsy at U.S. Academic Institutions. Curr Probl Diagn Radiol 48(5):462–466
44.
Khoury T, Kumar PR, Li Z, Karabakhtsian RG, Sanati S, Chen X et al (2016) Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions. Mod Pathol 29(1):25–33CrossRef
45.
Jabbar SB, Lynch B, Seiler S, Hwang H, Sahoo S (2017) Pathologic Findings of Breast Lesions Detected on Magnetic Resonance Imaging. Arch Pathol Lab Med 141(11):1513–1522CrossRef
46.
Chikarmane SA, Harrison BT, Giess CS, Pinkney DM, Gombos EC (2021) Lobular neoplasia detected at MRI-guided biopsy: imaging findings and outcomes. Clin Imaging 78:171–178CrossRef
47.
Michaels AY, Ginter PS, Dodelzon K, Naunheim MR, Abbey GN (2021) High-Risk Lesions Detected by MRI-Guided Core Biopsy: Upgrade Rates at Surgical Excision and Implications for Management. AJR Am J Roentgenol 216(3):622–632CrossRef
48.
Laws A, Katlin F, Nakhlis F, Chikarmane SA, Schnitt SJ, King TA (2022) Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. Ann Surg Oncol 29(3):1660–1667CrossRef
49.
Schmidt H, Arditi B, Wooster M, Weltz C, Margolies L, Bleiweiss I et al (2018) Observation versus excision of lobular neoplasia on core needle biopsy of the breast. Breast Cancer Res Treat 168(3):649–654CrossRef
50.
Matar R, Sevilimedu V, Park A, King TA, Pilewskie M (2022) Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. Ann Surg Oncol 29(3):1670–1679CrossRef
51.
Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P et al (2014) Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med 3(3):492–499CrossRef
52.
Shin SJ, Lal A, De Vries S, Suzuki J, Roy R, Hwang ES et al (2013) Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol 44(10):1998–2009CrossRef
53.
Shamir ER, Chen YY, Chu T, Pekmezci M, Rabban JT, Krings G (2019) Pleomorphic and Florid Lobular Carcinoma In Situ Variants of the Breast: A Clinicopathologic Study of 85 Cases With and Without Invasive Carcinoma From a Single Academic Center. Am J Surg Pathol 43(3):399–408CrossRef
54.
Sapino A, Frigerio A, Peterse JL, Arisio R, Coluccia C, Bussolati G (2000) Mammographically detected in situ lobular carcinomas of the breast. Virchows Arch 436(5):421–430CrossRef
55.
Kuba MG, Murray MP, Coffey K, Calle C, Morrow M, Brogi E (2021) Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision. Mod Pathol 34(8):1495–1506CrossRef
56.
Fadare O, Dadmanesh F, Alvarado-Cabrero I, Snyder R, Stephen Mitchell J, Tot T et al (2006) Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases. Am J Surg Pathol 30(11):1445–1453CrossRef
57.
Foschini MP, Miglio R, Fiore R, Baldovini C, Castellano I, Callagy G et al (2019) Eur J Surg Oncol 45(12):2279–2286
58.
Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B (2010) Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch Pathol Lab Med 134(7):1024–1028CrossRef
59.
Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C et al (2009) Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol 33(11):1683–1694CrossRef
60.
Zhong E, Solomon JP, Cheng E, Baum J, Song W, Hoda SA (2020) Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ: Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity. Am J Surg Pathol 44(8):1092–1103CrossRef
61.
Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP (2002) Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 15(10):1044–1050CrossRef
62.
Fasola CE, Chen JJ, Jensen KC, Allison KH, Horst KC (2018) Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. Breast J 24(1):66–69CrossRef
63.
Flanagan MR, Rendi MH, Calhoun KE, Anderson BO, Javid SH (2015) Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management. Ann Surg Oncol 22(13):4263–4269CrossRef
64.
Khoury T, Karabakhtsian RG, Mattson D, Yan L, Syriac S, Habib F et al (2014) Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology 64(7):981–993CrossRef
65.
De Brot M, KoslowMautner S, Muhsen S, Andrade VP, Mamtani A, Murray M et al (2017) Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Res Treat 165(2):411–420CrossRef
66.
Desai AA, Jimenez RE, Hoskin TL, Day CN, Boughey JC, Hieken TJ (2018) Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. Ann Surg Oncol 25(10):3064–3068CrossRef
67.
Nakhlis F, Harrison BT, Giess CS, Lester SC, Hughes KS, Coopey SB et al (2019) Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. Ann Surg Oncol 26(1):55–61CrossRef
68.
Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ (2008) Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol 32(11):1721–1726CrossRef
69.
Guo T, Wang Y, Shapiro N, Fineberg S (2018) Pleomorphic Lobular Carcinoma in Situ Diagnosed by Breast Core Biopsy: Clinicopathologic Features and Correlation With Subsequent Excision. Clin Breast Cancer 18(4):e449–e454CrossRef
70.
Carder PJ, Shaaban A, Alizadeh Y, Kumarasuwamy V, Liston JC, Sharma N (2010) Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology 57(3):472–478CrossRef
71.
Singh K, Sung CJ, Quddus MR (2020) Descriptive study comparing outcomes of classic and nonclassic lobular carcinoma in situ (florid and pleomorphic) initially diagnosed on core needle biopsy. Breast J
72.
Cserni G, Floris G, Koufopoulos N, Kovacs A, Nonni A, Regitnig P, et al. (2017) Invasive lobular carcinoma with extracellular mucin production-a novel pattern of lobular carcinomas of the breast. Clinico-pathological description of eight cases. Virchows Arch 471(1):3–12
73.
Singh K, Paquette C, Kalife ET, Wang Y, Mangray S, Quddus MR et al (2018) Evaluating agreement, histological features, and relevance of separating pleomorphic and florid lobular carcinoma in situ subtypes. Hum Pathol 78:163–170CrossRef
74.
75.
76.
Harrison BT, Nakhlis F, Dillon DA, Soong TR, Garcia EP, Schnitt SJ et al (2020) Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations. Mod Pathol 33(7):1287–1297CrossRef
77.
Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP (2011) Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med 135(6):737–743CrossRef
78.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) Breast. The AJCC Cancer Staging Manual. 7th Edition ed. New York, NY: Springer New York Dordrecht Heidelberg London
79.
Hortobagyi GN, Connolly JL, D'Orsi CJ, Edge SB, Mittendorf EA, Hugo HS, et al. (2017) Breast. The AJCC Cancer Staging Manual. 8th edn, pp 589–628
80.
Cardoso F, Kyrickides S, Ohno S, Penault-Lorca F, Poortmans P, Rubio IT, a, (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194–1220CrossRef
81.
Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M et al (2008) Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 32(5):773–783CrossRef
82.
Canas-Marques R, Schnitt SJ (2016) E-cadherin immunohistochemistry in breast pathology: uses and pitfalls. Histopathology 68(1):57–69CrossRef
83.
Grabenstetter A, Mohanty AS, Rana S, Zehir A, Brannon AR, D’Alfonso TM et al (2020) E-cadherin immunohistochemical expression in invasive lobular carcinoma of the breast: correlation with. Hum Pathol 102:44–53CrossRef
84.
Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T et al (2013) Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol 37(7):e1–e11CrossRef
85.
Dabbs DJ, Bhargava R, Chivukula M (2007) Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol 31(3):427–437CrossRef
86.
Mohsin SK, O’Connell P, Allred DC, Libby AL (2005) Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat 90(3):249–256CrossRef
87.
Sakr RA, Schizas M, Carniello JV, Ng CK, Piscuoglios S, Giri D et al (2016) Targeted captire massive parallel sequencing analysis of LCIS and invasive lobular cancer. Mol Oncol 10(2):360–270CrossRef
88.
Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M et al (2005) Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 207(1):1–13CrossRef
89.
Boldt V, Stacher E, Halbwedl I, Popper H, Hultschig C, Moinfar F et al (2010) Positioning of necrotic lobular intraepithelial neoplasias (LIN, grade 3) within the sequence of breast carcinoma progression. Genes Chromosomes Cancer 49(5):463–470
90.
Shamir ER, Chen YY, Krings G (2020) Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma. Mod Pathol 33(6):1078–1091CrossRef
91.
Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES et al (2016) Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Ann Surg Oncol 23(3):722–728CrossRef
Metadaten
Titel
The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS
verfasst von
Edi Brogi
Publikationsdatum
14.05.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 6/2022
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-022-03299-3

Weitere Artikel der Ausgabe 6/2022

Virchows Archiv 6/2022 Zur Ausgabe

Obituary

Obituary Prof. Ondrej Hes

Original Article

Investigation of -PRKACA/-PRKACB fusion genes in oncocytic tumors of the pancreatobiliary and other systems

Original Article

Clinical significance and interrelations of PD-L1 expression, Ki-67 index, and molecular alterations in sporadic medullary thyroid carcinoma from a Chinese population

Original Article

Long noncoding RNA CLAN promotes lymphangiogenesis in the colorectal carcinoma

Original Article

FABP1 expression in human tumors: a tissue microarray study on 17,071 tumors

News

In this issue

Neu im Fachgebiet Pathologie

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Molekularpathologische Untersuchungen im Wandel der Zeit

11.04.2024 | Pathologie | Schwerpunkt: Next Generation Pathology

Vergleichende Pathologie in der onkologischen Forschung

Open Access 08.04.2024 | GIST | CME

Gastrointestinale Stromatumoren
Wo stehen wir?

03.04.2024 | Zielgerichtete Therapie | Schwerpunkt: Next Generation Pathology

Personalisierte Medizin in der Onkologie